Forge Biologics Announces Eight Presentations at the Upcoming 2023 Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Forge Biologics, a leading manufacturer of genetic medicines, announced today that eight presentations, including four oral presentations, will be delivered during the upcoming 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place May 16-20, 2023,…

Read MoreForge Biologics Announces Eight Presentations at the Upcoming 2023 Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Angelini Pharma and JCR Pharmaceuticals Announce Global Collaboration for the Development and Commercialization of Novel Biologic Therapies in Epilepsy

Angelini Pharma, part of the privately owned Angelini Industries, and JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) announced today that they entered into an exclusive global development and commercialization agreement for the development of novel biologic therapies that applies J-Brain Cargo®, blood-brain…

Read MoreAngelini Pharma and JCR Pharmaceuticals Announce Global Collaboration for the Development and Commercialization of Novel Biologic Therapies in Epilepsy

Cellular Origins Partners With ScaleReady to Simplify, Standardise, and Automate Cell Therapy Manufacturing

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective and efficient manufacture of cell and gene therapies (CGTs), has today announced a collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf that brings together…

Read MoreCellular Origins Partners With ScaleReady to Simplify, Standardise, and Automate Cell Therapy Manufacturing

Apyx Medical Corporation Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its first quarter ended March 31, 2023, and updated financial expectations for the full year…

Read MoreApyx Medical Corporation Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook

Extend Biosciences Announces Positive Data from Phase 1 Trial of EXT608 for the Treatment of Hypoparathyroidism

Extend Biosciences (“ExtendBio”), a clinical stage biopharmaceutical company utilizing a proprietary platform technology to develop advanced therapeutic peptides, today announced positive results from its first-in-human trial of EXT608. An interim data analysis shows that EXT608 was safe and well tolerated,…

Read MoreExtend Biosciences Announces Positive Data from Phase 1 Trial of EXT608 for the Treatment of Hypoparathyroidism

Bicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023

Bicycle Therapeutics plc (NASDAQ: BCYC) and Orano Med, two biotechnology companies respectively, announce pre-clinical results. Bicycle is pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology and Orano Med is developing innovative radioligand…

Read MoreBicycle Therapeutics and Orano Med Present Preclinical Bicycle® Radio-Conjugate Data at TIDES 2023

National Vision Holdings, Inc. Reports First Quarter 2023 Financial Results

National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today reported its financial results for the first quarter ended April 1, 2023. Reade Fahs, chief executive officer, stated, “Amidst an uncertain macro environment, we delivered positive comparable sales…

Read MoreNational Vision Holdings, Inc. Reports First Quarter 2023 Financial Results

Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook

Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2022 (period ended March 31, 2023), delivering or exceeding management guidance, driven by the performance of its Growth & Launch Products. Takeda president and chief executive officer, Christophe Weber, commented:“FY2022…

Read MoreTakeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook

HeartBeam Completes $25 Million Capital Raise and Updates 2023 Strategic Focus and Financial Guidance

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform to help physicians detect heart attacks anytime, anywhere as well as diagnose other common heart conditions today announced closing of its…

Read MoreHeartBeam Completes $25 Million Capital Raise and Updates 2023 Strategic Focus and Financial Guidance

IQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2023. First-Quarter 2023 Operating ResultsRevenue for the…

Read MoreIQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance